Company intelligence / Profile preview
199 Biotechnologies
London, England, United Kingdom199.bio ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Preclinical
01
Overview
199 Biotechnologies develops therapies aimed at reversing cellular aspects of aging and treating age-related diseases through epigenetic reprogramming. Their preclinical work demonstrates efficacy in multiple cancer cell lines—especially brain cancers—and they are optimizing both mRNA-based and cell therapy platforms. The company’s organ-on-a-chip system accelerates discovery by simulating human organ systems for high-throughput screening. No clinical results have been published as the company remains at the preclinical research stage.
- Therapeutic areas
- OtherOncology
- Modalities
- mRNA therapeuticsCell therapyGene therapy (partial reprogramming)Epigenetic reprogramming
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborations with University College London (UCL) scientistsstrategic academic partnerships mentioned but not named specifically.
Beyond the preview
Go deeper on 199 Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 199 Biotechnologies.